Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety

References

• Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011;66(3):317–330.
   PubMed Web of Science ®Google Scholar
• Gaig P, Olona M, Munoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004;14(3):214–220.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–887.
   PubMed Web of Science ®Google Scholar
• Curto-Barredo L, Ribs Archilla L, Roura Vives G, et al. Observational retrospective cohort study of 549 patients with chronic spontaneous urticaria. ePoster presented at the 25th European Academy of Dermatology and Venereology Congress https://www.eadv.org/; 2016. Presentation number p2322. Available from: https://user-cc0betr.cld.bz/Final-Programme-Vienna/2
   Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64(10):1427–1443.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2014;69(7):e1–29.
   PubMed Web of Science ®Google Scholar
• Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, et al. Up-dosing non-sedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153–1165.
   PubMed Web of Science ®Google Scholar
• Richards RN. Side effects of short-term oral corticosteroids. J Cutan Med Surg. 2008;12(2):77–81.
   PubMed Web of Science ®Google Scholar
• Irving PM, Gearry RB, Sparrow MP, et al. Review article: appropriate use of corticosteroids in Crohn’s disease. Aliment Pharmacol Ther. 2007;26(3):313–329.
   PubMed Web of Science ®Google Scholar
• Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001;164(8 Pt 2):S6–11.
   PubMed Web of Science ®Google Scholar
• Xolair. Prescribing information. 2015; Available at: http://www.gene.com/download/pdf/xolair_prescribing.pdf. [Last accessed September 2016]
   Google Scholar
• EMEA. Xolair SmPC 2016; Available at: http://ec.europa.eu/transparency/regdoc/rep/3/2014/EN/3-2014-1463-EN-F1-1-ANNEX-1.PDF. [Last accessed September 2016]
   Google Scholar
• Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy, Asthma Immunol. 2007;99(2):190–193.
   PubMed Web of Science ®Google Scholar
• Godse KV. Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol. 2008;74(2):157–158.
   PubMed Web of Science ®Google Scholar
• Spector SL, Tan RA. Therapeutic alternatives for chronic urticaria: additional reports on omalizumab. Ann Allergy Asthma Immunol. 2008;101(6):647.
   PubMed Web of Science ®Google Scholar
• Romano C, Sellitto A, De Fanis U, et al. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol. 2010;104(1):95–97.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122(3):569–573..
   PubMed Web of Science ®Google Scholar
• Ferrer M, Gamboa P, Sanz ML, et al. Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol. 2011;127(5):1300–1302.
   PubMed Web of Science ®Google Scholar
• Gober LM, Sterba PM, Eckman JA, et al. Effect of Anti-IgE (Omalizumab) in chronic idiopathic urticaria (CIU) patients. J Allergy Clin Immunol. 2008;121(2):S147–S147..
   Web of Science ®Google Scholar
• Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567–73.e1..
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202–209e5..
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935..
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–109..
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67–75..
   PubMed Web of Science ®Google Scholar
• Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016;71(8):1135–1144.
   PubMed Web of Science ®Google Scholar
• Goh CL, Tan KT. Chronic autoimmune urticaria: where we stand?. Indian J Dermatol. 2009;54(3):269–274.
   PubMedGoogle Scholar
• Presta LG, Lahr SJ, Shields RL, et al. Humanization of an Antibody-Directed against Ige. Journal of Immunology. 1993;151(5):2623–2632.
   PubMed Web of Science ®Google Scholar
• Holgate S, Buhl R, Bousquet J, et al. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med. 2009;103(8):1098–1113.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2016. 15 November 2016. DOI:10.1111/all.13083
   PubMedGoogle Scholar
• Hochhaus G, Brookman L, Fox H, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19(6):491–498.
   PubMed Web of Science ®Google Scholar
• Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742–1750e4.
   PubMed Web of Science ®Google Scholar
• Casale TB, Bernstein JA, Maurer M, et al. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J Allergy Clin Immunol Pract. 2015;3(5):743–50e1..
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137(2):474–481.
   PubMed Web of Science ®Google Scholar
• Ferrer M, Giménez-Arnau A, Saldana D, et al. Identification of parameters that could predict time to return of symptoms after stopping omalizumab treatment: exploratory analysis of phase III data from patients with chronic idiopathic/spontaneous urticaria. Allergy 2016;71(S102):185. Available from: http://onlinelibrary.wiley.com/doi/10.1111/all.12972/pdf
   Google Scholar
• Labrador-Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther. 2013;13(9):1225–1228.
   PubMed Web of Science ®Google Scholar
• Metz M, Ohanyan T, Church MK, et al. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150(3):288–290.
   PubMed Web of Science ®Google Scholar
• Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria. Ann Allergy Asthma Immunol. 2015;115(2):126–129.
   PubMed Web of Science ®Google Scholar
• Gonul M, Ozenergun Bittaci A, Ergin C. Omalizumab-induced triphasic anaphylaxis in a patient with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2016 Nov;30(11):e135-e136.
   PubMed Web of Science ®Google Scholar
• Ertas R, Ozyurt K, Yildiz S, et al. Adverse reaction to omalizumab in patients with chronic urticaria: flare up or ineffectiveness?. Iran J Allergy Asthma Immunol. 2016;15(1):82–86.
   PubMed Web of Science ®Google Scholar
• Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191.
   PubMed Web of Science ®Google Scholar
• Abraham I, Alhossan A, Lee CS, et al. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593–610.
   PubMed Web of Science ®Google Scholar
• O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197–201.
   PubMed Web of Science ®Google Scholar
• Sussman G, Hebert J, Gulliver W, et al. Insights and advances in chronic urticaria: a Canadian perspective. Allergy Asthma Clin Immunol. 2015;11(1):7.
   PubMed Web of Science ®Google Scholar
• O’Donnell BF. Urticaria: impact on quality of life and economic cost. Immunol Allergy Clin North Am. 2014;34(1):89–104.
   PubMed Web of Science ®Google Scholar
• Gimenez-Arnau AM, Spector S, Antonova E, et al. Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies. Clin Transl Allergy. 2016;6:32.
   PubMed Web of Science ®Google Scholar
• Balp M, Chambenoit O, Chiva-Razavi S, et al. Work productivity and activity impairment among chronic spontaneous/idiopathic urticaria patients: results From the first international burden of illness study (Assure-Csu). Value Health. 2015;18(7):A427.
   PubMedGoogle Scholar
• Tian H, Chambenoit O, Chiva-Razavi S, et al. Healthcare resource utilisation among chronic spontaneous/idiopathic urticaria patients- findings from the first international burden of illness study (Assure-Csu). Value Health. 2015;18(7):A424.
   Google Scholar
• Balp MM, Vietri J, Tian H, et al. The impact of chronic urticaria from the patient’s perspective: a survey in five european countries. Patient. 2015;8(6):551–558.
   PubMedGoogle Scholar
• Vietri J, Turner SJ, Tian H, et al. Effect of chronic urticaria on US patients: analysis of the national health and wellness survey. Ann Allergy Asthma Immunol. 2015;115(4):306–311.
   PubMed Web of Science ®Google Scholar
• Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60(8):1073–1078.
   PubMed Web of Science ®Google Scholar
• Mlynek A, Magerl M, Hanna M, et al. The German version of the chronic urticaria quality-of-life questionnaire: factor analysis, validation, and initial clinical findings. Allergy. 2009;64(6):927–936.
   PubMed Web of Science ®Google Scholar
• Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012;67(10):1289–1298.
   PubMed Web of Science ®Google Scholar
• Stull DE, McBride D, Houghton K, et al. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): a post-hoc analysis from 2 randomized, double-blind, placebo-controlled phase 3 trials of omalizumab. J Am Acad Dermatol. 2015;72(5):Ab43–Ab43.
   Web of Science ®Google Scholar
• Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-72, 1372 e1-6.
   PubMed Web of Science ®Google Scholar
• Savic S, Marsland A, McKay D, et al. Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. Allergy Asthma Clin Immunol. 2015;11(1):21.
   PubMed Web of Science ®Google Scholar
• Gimenez-Arnau A, Velasco M, Armario Hita JC, et al. Omalizumab: what benefits should we expect?. Eur J Dermatol. 2016;26(4):340–344.
   PubMed Web of Science ®Google Scholar
• Target My Hives. [Last accessed January 10, 2017]. Available at: http://myhives.com/.
   Google Scholar
• Urticaria Day. [Last accessed January 10, 2017]. Available from: http://urticariaday.org/.
   Google Scholar
• Chronic Urticaria Registry. [Last accessed January 10, 2017]. Available at: http://www.urticaria-registry.com/.
   Google Scholar
• Deza G, Bertolín-Colilla M, Pujol RM, et al. Down-regulation of basophil FcεRI expression in CSU during omalizumab therapy. GA²LEN Global Urticaria Forum abstract book. [Last accessed January 10, 2017]. Available from: http://www.globalurticariaforum.org/.
   Google Scholar
• Kocaturk E, Kuteyla Can P, Etikan Akbas P Management of chronic inducible urticaria according to guidelines; do same treatment algorithms work? GA²LEN Global Urticaria Forum abstract book. [Last accessed January 10, 2017]. Available from: http://www.globalurticariaforum.org/.
   Google Scholar
• Barron C, Saperia C, Kobric D, et al. Chronic spontaneous urticaria; centre of excellence. GA²LEN Global Urticaria Forum abstract book. [Last accessed January 10, 2017]. Available from: http://www.globalurticariaforum.org/.
   Google Scholar
• Maurer M, Schütz A, Weller K, et al. Omalizumab in cold urticaria: results of a randomized placebo-controlled trial. GA²LEN Global Urticaria Forum abstract book. [Last accessed January 10, 2017]. Available from: http://www.globalurticariaforum.org/.
   Google Scholar